Hydronephrosis natural history, complications and prognosis

	Hydronephrosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hydronephrosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hydronephrosis natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hydronephrosis natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hydronephrosis natural history, complications and prognosis
CDC on Hydronephrosis natural history, complications and prognosis
Hydronephrosis natural history, complications and prognosis in the news
Blogs on Hydronephrosis natural history, complications and prognosis
Directions to Hospitals Treating Hydronephrosis
Risk calculators and risk factors for Hydronephrosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include Hyperkalemia, Metabolic acidosis, and Distal renal tubular acidosis.

OR

Prognosis is generally excellent, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
The symptoms of (disease name) typically develop ___ years after exposure to ___.
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
[Subtype of disease/malignancy] is associated with the most favorable prognosis.
The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.

↑ Kozeny GA, Hurley RM, Vertuno LL, Bansal VK, Zeller WP, Hano JE (1986). "Hypertension, mineralocorticoid-resistant hyperkalemia, and hyperchloremic acidosis in an infant with obstructive uropathy". Am. J. Nephrol. 6 (6): 476–81. doi:10.1159/000167258. PMID 3565506.
↑ Chandar J, Abitbol C, Zilleruelo G, Gosalbez R, Montané B, Strauss J (February 1996). "Renal tubular abnormalities in infants with hydronephrosis". J. Urol. 155 (2): 660–3. PMID 8558697.
↑ Lee JH, Choi HS, Kim JK, Won HS, Kim KS, Moon DH, Cho KS, Park YS (April 2008). "Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection". J. Urol. 179 (4): 1524–8. doi:10.1016/j.juro.2007.11.090. PMID 18295269.